leadf
logo-loader
viewBiocept Inc
(
NASDAQ:BIOC
)

Biocept to host webinar with leading neuro-oncologists to discuss its cerebrospinal fluid assay (CSF) for diagnosing and managing tumors

Its CSF assay provides enhanced sensitivity compared to the current standard-of-care for tumors that have metastasized to the central nervous system

Biocept Inc - Biocept Inc to host a webinar featuring leading neuro-oncologists to discuss the use of its cerebrospinal fluid  assay for diagnosing and managing tumors that have metastasized to the central nervous system
The webinar will be held on April 8 at 12 pm ET

Biocept Inc (NASDAQ:BIOC) (FRA:B003) will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column.  

The company said its CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard-of-care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression. 

READ: Biocept posts first-ever quarterly profit and balloons 4Q revenue to $18.5M on strength of coronavirus testing

“Our goal is to establish our CSF assay as the new standard of care for the diagnosis of patients with suspected cancer metastasis to the CNS under National Comprehensive Cancer Network guidelines,” said Dr Michael Dugan, Biocept’s chief medical officer, in a statement Thursday. 

“We have already gained substantial interest among neuro-oncologists and other cancer specialists from nearly two dozen leading academic institutions across the country. Most of these physicians have already ordered our CSF assay, with many becoming repeat users."

Dr Dugan added: “The CSF assay addresses a high unmet clinical need as current diagnostic tools for patients with brain metastases are inadequate or imprecise for assessing therapy response; however, many therapies are now available that offer substantial promise for improved survival and resolution of symptoms. Between 10% and 30% of adult patients with cancer, depending on the type, will develop brain metastases. We estimate this market opportunity at more than $1 billion annually.”

The webinar will be held on April 8 at 12 pm ET. Participants can pre-register or register at the webinar start time here. The webinar also will be available live and archived at https://ir.biocept.com/.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Follow
NASDAQ:BIOC

Price: 4.07 USD

Market Cap: $59.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept approved for expanded Medicare coverage for its Target Selector...

Biocept Inc (NASDAQ:BIOC) (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall tells Proactive it has received a positive final Local Coverage Determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program, which will expand Medicare coverage for use of Biocept’s Target...

on 07/27/2021

2 min read